Nirmal Mulye, the chief executive of a small drug company called Nostrum Laboratories, defended his decision to the Financial Times to quadruple the price of a 65-year-old antibiotic.
What he's saying: “I think it is a moral requirement to make money when you can . . . to sell the product for the highest price... I agree with Martin Shkreli that when he raised the price of his drug he was within his rights because he had to reward his shareholders... This is a capitalist economy and if you can’t make money you can’t stay in business.”